#ivd market 2019
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
28.6 is the average number of monthly visits per US mobile user.
Link
The remarkable growth rate of 6% is attributed to growing mergers & collaboration in this space coupled with growing government support in several...
0 notes
Link
Recent study published by Adroit Market Research on Global in vitro diagnostics (ivd) market evaluates the market demand and forecast based on various forecasting models.
0 notes
Link
The remarkable growth rate of 6% is attributed to growing mergers & collaboration in this space coupled with growing government support in several developing economies to tackle growing healthcare needs. Molecular diagnostics have emerged as one of the leading and fastest-growing sectors of the IVD industry
0 notes
Text
In Vitro Diagnostics (IVD) Quality Control Market Analysis, Demand & Forecast to 2020 – Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK)
Market Overview
The global in vitro diagnostics quality control market was valued at USD 1.5 billion in 2021 and it is anticipated to grow further up to USD 2.2 billion by 2031, at a CAGR of 3.7% during the forecast period.
The effectiveness of in vitro diagnostic tests, including those for pathogen identification using in vitro nucleic acid testing, healthcare-associated illnesses (HAIs) such as pneumonia, urinary tract infections, and others, is assessed using IVD quality controls. These products primarily concentrate on defect detection, quality control, and validation panels like the Blood Culture (BCID) Control Panel, Human Papillomavirus (HPV) Control Panel, and others to support in the implementation and monitoring of the performance of clinical and research laboratories, blood diagnostic centers, and IVD manufacturers.
View Detailed Report Description: https://www.globalinsightservices.com/reports/in-vitro-diagnostics-ivd-quality-control-market/
Market Dynamics
As the burden of various diseases increases globally, so has the number of laboratory tests. The number of laboratories in both the public and private sectors has increased in response to this need. With the start of the COVID-19 pandemic in December 2019, the demand for diagnostic tests has skyrocketed. Many government organizations have established new laboratories in response to this epidemic and to increase laboratory testing capacity. The majority of nations need clinical laboratories to get regulatory body accreditation before performing diagnostic tests. Additionally, accreditation to ISO 15189:2012 and other comparable standards is turning into a requirement in many nations. Authorities assess a laboratory’s competency and quality system during the accreditation process using predetermined standards. While some European nations, including Belgium, France, Hungary, Ireland, and Lithuania, require accreditation for a variety of laboratory tests, others, like Finland, the Netherlands, Sweden, Switzerland, and the UK, have practically finished the process.
It costs a lot of money to set up a QC process in a clinical laboratory. Additionally, laboratories must keep a specialized staff on hand to oversee the QC system. Moreover, regardless of the number of tests conducted, QC procedures are expensive. As a result, QC methods are particularly expensive to adopt for clinical laboratories that perform few diagnostic tests. This is predicted to lead to a lesser adoption of QC procedures, along with budgetary restrictions in many hospitals and laboratories in developed and emerging nations.
Get Free Sample Copy of This Report: https://www.globalinsightservices.com/request-sample/GIS10301
The key players studied in the global in vitro diagnostic quality control market are Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), Abbott Laboratories (US), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Fortress Diagnostics (UK), SERO AS (US), Sysmex Corporation (Japan), Ortho-Clinical Diagnostics (US), and Helena Laboratories Corporation (US) among others.
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1–833–761–1700
2 notes
·
View notes
Text
From Lab-on-a-Chip to Industrial Innovation: Milestones in Microfluidic Technology
The global market for microfluidic products surged to $9.98 billion in 2019, with microfluidic devices accounting for $3.48 billion of this figure. A notable trend in the industry is the ongoing acquisition of microfluidic companies by larger enterprises, signaling a trajectory of accelerated growth through capital infusion.
In the industrial landscape, in vitro diagnostics (IVD) stands out as the primary sector for microfluidic applications, driven by its lucrative returns. Demographic shifts, particularly aging populations, contribute to an escalating demand for microfluidic chips. Moreover, governmental policies prioritize the advancement of the microfluidics industry, a focus that has intensified amidst the backdrop of the pandemic. Moving forward, the critical hurdles facing microfluidic chip technology revolve around manufacturing costs and scalability. Achieving scalable production processes and cost reduction measures while maintaining product standardization and minimizing variations are imperative objectives.
The evolution of modern technology emphasizes miniaturization, integration, and intelligence. Microelectromechanical systems (MEMS) have played a pivotal role in this evolution, enabling the transition from bulky electronic systems to compact integrated circuit chips and handheld devices like smartphones. Similarly, microfluidic chips, often referred to as Lab-on-a-Chip technology, epitomize the manipulation of fluids at micro- and nanoscales. These chips condense essential laboratory functionalities, such as sample preparation, reaction, separation, and detection, onto a compact chip, typically a few square centimeters in size. The hallmark of microfluidic chips lies in their capacity for flexible integration and scaling of diverse unit technologies within a controllable microplatform.
Originating from MEMS technology, early microfluidic chips underwent fabrication processes on substrates like silicon, metals, polymers, glass, and quartz. These processes yielded microstructure units such as fluid channels, reaction chambers, filters, and sensors, with dimensions ranging from micrometers to sub-millimeters. Subsequent fluid manipulation within these microstructures enabled automated execution of biological laboratory procedures, including extraction, amplification, labeling, separation, and analysis, or cell manipulation and analysis.
In the early 1990s, A. Manz et al. demonstrated the potential of microfluidic chips as analytical chemistry tools by achieving electrophoretic separation—a technique previously confined to capillaries—on chips. Subsequently, spurred by the U.S. Department of Defense's requisition for portable biochemical self-test equipment, research in microfluidic chips burgeoned globally. Throughout the 1990s, microfluidic chips primarily served as platforms for analytical chemistry, often interchangeably referred to as "Micro Total Analysis Systems" (u-TAS). Consequently, these chips found applications across diverse fields, including biomedical diagnostics, food safety, environmental monitoring, forensics, military, and aerospace sciences.
Key milestones in the advancement of microfluidic chips include G. Whitesides et al.'s 2000 publication on PDMS soft lithography and S. Quake et al.'s 2002 article on "large-scale integration of microfluidic chips" featuring microvalve and micropump controls. These seminal works propelled microfluidic chips beyond the confines of traditional analytical systems, unlocking their potential for significant scientific and industrial applications. For instance, microfluidic chips enable the execution of combinatorial chemical reactions or droplet techniques, facilitating drug synthesis, high-throughput screening, and large-scale nanoparticle or microsphere production. In essence, microfluidic chips pave the way for the realization of a "chemical plant or pharmaceutical lab on a chip."
0 notes
Text
Navigating the Transition: Understanding the UKCA Marking Certification Process for Medical Devices
The United Kingdom’s choice to leave the European Union has achieved tremendous changes, not just in that frame of mind of exchange and guidelines, but in addition to the accreditation processes governing the conformity of products. One pivotal part of this change is the entry of the UKCA (UK Conformity Assessed) marking, which replaces the CE marking for merchandise put on the UK market.
In this article, we will dig into the UKCA Marking in UAE certification process, giving bits of knowledge to assist organizations with exploring this basic change.
Scope and Applicability
Understanding whether an item requires UKCA marking is the most important phase in the certificate process. Not all products are dependent upon the new guidelines, and organizations should cautiously evaluate the particular necessities appropriate to their products. Certain items might in any case utilize CE marking, assuming that they are being sold in the EU and meet European guidelines.
What is UKCA Marking?
The United Kingdom Conformity Assessment Mark or UKCA Mark for short is what could be compared to the EU CE marking. UKCA Mark is a substantial pointer that a medical device adjusts to significant UK Guidelines. The United Kingdom Conformity Assessment marking is required for medical devices sold available in Great Britain (Britain, Wales, and Scotland).
United Kingdom’s Medicines and Health Care Products Regulatory Agency (MHRA) On 18 September 2019, distributed new rules to direct medical devices after Brexit. The UKCA won't be perceived in the EU, EEA, or Northern Ireland items actually require a CE marking available to be purchased in these business sectors.
The maker or their approved delegate will be answerable for fastening the UKCA Certification to the product, which is a similar rule concerning CE marking yet for the UK market.
What is UKCA Marking for Medical Devices?
The UKCA marking is a logo that implies a medical device's compliance with the UK MDR 2002 requirements. This mark certifies that the device is protected, fit for its planned reason, and conforms to the regulations connected with safety. It is a compulsory necessity for medical devices planned for the Great Britain market, which incorporates Britain, Wales, and Scotland.
Who Needs UKCA Marking for Medical Devices?
In the event that you are associated with the assembling, delivery, or import of medical devices in the UK, you might be expected to acquire UKCA marking. This incorporates:
Medical device makers situated in the UK
Merchants of medical devices in the UK
Organizations importing medical devices into the UK
Technical Documentation and Standards
The core of the certificate process lies in the preparation & accommodation of technical documentation. Makers should order an exhaustive record framing the item's plan, details, and conformity with significant UKCA Marking standards. Experience with these norms is significant, and organizations might have to adjust their cycles to meet the particular measures set by UK specialists.
Documentation Required for UKCA Certification:
Records
Formats
Forms
Checklist
Standard Operating Procedure (SOP)
Plant Master File
Mission & Vision
Objectives
Policy
System Procedure
System Manual
Product Testing
Technical File, Product Master File (TCF)
The extent of Documented Information differs as per:
Notify body Certificate
Self Certification or Compliance Certification
Directive in which product classified
Testing requirements of products
Product and its uses
Key Requirements for Placing Medical Devices in the Great Britain Market:
New Product Marking (UKCA Mark): Guarantee that your medical device delivers the UKCA mark.
Registration with MHRA:: Every single medical device and IVD should be enrolled with MHRA before they can be made available.
UK Responsible Person: In the event that you are a producer situated external the UK, you should select a single UK-reliable individual.
Classification: Medical devices in the UK are classified as Class I, Class IIa, Class IIb, and Class III, like the European Union’s plan. Class I devices are generally safe, while Class III devices are high-risk.
Registration Process for Medical Devices (UKCA Marking Process)
The Medicines and Healthcare Products Regulatory Agency is the UK's regulatory power answerable for guaranteeing that meds and medical devices are protected and compelling.
Classification: Decide the order of your medical device as indicated by the MDR.
Conformity Assessment: Lead a conformity evaluation to show that your device meets security and execution requirements.
Specialized Documentation: Get ready tech documentation that incorporates device depictions, planned use, and medical information.
Application Submission: Present your application to the MHRA through the Medical Devices Information System (MDIS).
Assessment: MHRA will assess your application and specialized documentation to guarantee compliance with safety and execution prerequisites.
Registration Certificate: In the event that your application is effective, MHRA will give an enrollment declaration, permitting you to sell your medical device in the UK.
Additional Points:
A progress period exists for certain item products, permitting the utilization of existing CE marking until Dec. 12, 2027.
The particular process can shift contingent on your item type and intricacy.
Conclusion: A Roadmap for Compliance
Exploring the UKCA Marking in UAE certification process requires a key and informed approach. Organizations should put time and assets into understanding the subtleties of the new regulatory scene, guaranteeing that their items fulfill the expected guidelines for the UK market.
As the business climate keeps on developing, remaining adaptable and receptive to changes will be vital to keeping an upper hand and guaranteeing continuous admittance to the UK market. By embracing the UKCA marking process for medical devices as a chance for development and compliance, organizations can unhesitatingly explore the change and secure their situations in the post-Brexit time.
0 notes
Text
Microfluidics Market Regional & Demand Analysis
Microfluidics Market by Product (Devices, Components (Chip, Sensor, Pump, Valve)), Application (IVD (POC, Clinical, Veterinary), Research, Manufacturing, Therapeutics), End User (Hospital, Diagnostic Center, Academic Institutes), and Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)
The Microfluidics Market size is projected to reach a CAGR of 24.6% from 2022 to 2028.
Microfluidics is a medical approach involving the precise control of small fluid samples for medical analysis. The sample sizes in microfluidics range from microliters to picolitres. At such low volumes, the transportation of fluid is governed significantly by its mass.
Growing technological advancements in diagnostic devices, rising demand for microfluidics technology, and rising incidence of chronic diseases are some of the factors that have supported long-term expansion for Microfluidics Market.
The COVID-19 pandemic has impacted the overall microfluidics industry in positive ways. The demand for rapid diagnostic tests, POC tests, and IVD devices with microfluidic technology utilized in drug discovery and COVID-19 testing has witnessed a significant demand.
Get a Sample Copy of the Report:https://www.delvens.com/get-free-sample/microfluidics-market-trends-forecast-till-2028
Regional Analysis
North America is expected to account for the largest share of the microfluidics market. North America has various additional advantages—investment initiatives by governments and the presence of high-quality infrastructure for clinical and laboratory research.
Key Players
uFluidix
Bio-Rad Laboratories Inc.
Fluidigm Corporation
Illumina Inc.
PerkinElmer, Inc
Parker Hannifin Corporation
IDEXX Corporation
Fluigent SA
Aignep S.P.A.
Camozzi Automation SPA Societá Unipersonale
Dolomite microfluidics
To Grow Business Revenue, Make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/microfluidics-market-trends-forecast-till-2028
Recent Developments
In March 2020, Parker-Hannifin Corporation (US) launched the LM-Pro linear motor proportional valves for the ventilators market.
In March 2020, Bio-Rad Laboratories Inc. (US) launched the SARS CoV-2 Standard to support laboratory assay validation of COVID-19 testing Germitec S.A. (France) received approval for the UV reprocessor from the FDA in April 2019.
Reasons to Acquire
Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors
Gain authentic and granular data access for Microfluidics Market so as to understand the trends and the factors involved behind changing market situations
Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns
Get Direct Order of the Report: https://www.delvens.com/checkout/microfluidics-market-trends-forecast-till-2028
Report Scope
Microfluidics Market is segmented into type, application, end user and region.
On the basis of Type
Microfluidic-based devices
Microfluidic Components
On the basis of Application
In-vitro diagnostics
Pharmaceutical & Life Science Research and Manufacturing
Therapeutics
On the basis of End-User
Hospitals & Diagnostic Centers
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
On the basis of Region
Asia Pacific
North America
Europe
South America
Middle East & Africa
Read More:
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
0 notes
Text
Anatomic Pathology Market Detailed Survey On Key Trends, Leading Players & Revolutionary Opportunities 2030
The global anatomic pathology market forecast is set to reach US$ 61.1 Mn in revenues by 2030, according to a new market study by ESOMAR-certified market research firm, Future Market Insights (FMI).
The anatomic pathology market is subject to integrating medical informatics standards to meet specific healthcare requirements by curtailing costs and improvising on efficiency.
Pathology laboratories are on the verge of refurbishment as new-fangled disease diagnostic models are making a beeline therein.
As of now, lymphoma, breast cancer, colorectal cancer, prostate cancer, cervical cancer, and lung cancer are a part of anatomic pathology.
Get Sample Report + Related Graphs & Charts @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12370
Key Takeaways
The instruments are subject to technological advancements, which would minimize errors. This factor is expected to drive the anatomic pathology market between 2022 and 2030
Consumables are expected to hold the largest market share due to low cost, high availability, and good purchase rate of probes and reagents
Academic research is bound to pick up pace in the forecast period owing to growing implementation of anatomic pathology in biomarker profiling and tumor examination
Preference to personalized therapies is prompting putative biomarkers being discovered. This factor is expected to be one of the key growth drivers
Key Participant Insights
The key market players are focusing on technological upgradations and expansion strategies to keep themselves fiercely competitive.
For instance –
In Jul 2020, Bio SB tabled its Fast Mohs PolyDetector Plus Detection System, which comes across as a super sensitive nonbiotin monovalent Fab micropolymer immunohistochemistry system to detect IVD antibodies for squamous cell carcinoma, basal cell carcinoma, and melanoma.
In Jan 2019, Quest Diagnostics announced completion of acquisition of the US laboratory services business that belonged to Oxford Immunotec (the T-Spot and Accutix tick-borne disease testing services, since then, are part of Quest’s infectious disease testing services.
In 2018, Leica Microsystems entered into a collaboration with Thermo Fisher to develop an integrated cryotomography workflow with regards to research.
Expand operations in the future – To get requisite details, ask for a custom report@ https://www.futuremarketinsights.com/customization-available/rep-gb-12370
The other players in the veterinary imaging market include
Laboratory Corporation of America Holdings
Sakura Finetek USA, Inc.
F.Hoffmann-La Roche AG
Cardinal Health, Inc.
BioGenex
NeoGenomics
Agilent Technologies
The US continues to be one of the leading markets for anatomic pathology market globally. Strong presence of some of the leading players, combined with relatively easier funding for R&D will drive the US anatomic pathology market during the assessment period.
The Europe anatomic pathology market is also likely to grow at a brisk pace during the assessment period. The growth will remain concentrated in Western Europe, as has been the case traditionally.
Asia Pacific represents a high growth market for anatomic pathology stakeholders. Many countries in the region are renewing their focus on healthcare, as the current Covid-19 crisis has reinforced the necessity of a robust healthcare system.
Want more insights?
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global anatomic pathology market is segmented in detail to cover every aspect and present a complete market intelligence approach to the reader.
The study provides compelling insights on anatomic pathology market on the basis of product & services type (Instruments (Microtomes & Cryostat, Tissue processors, Automatic Stainers, and Other products), consumables (Reagents & Antibodies, Probes & Kits, and Others), application (Disease Diagnosis, Drug Discovery and Development, and Others), and services (histopathology, cytopathology)) across seven geographies.
0 notes
Text
in vitro diagnostics quality control Market Pegged for Robust Expansion by 2031 | Type, Application, Scope & Key Companies
The global in vitro diagnostics quality control market was valued at USD 1.5 billion in 2021 and it is anticipated to grow further up to USD 2.2 billion by 2031, at a CAGR of 3.7% during the forecast period.
The effectiveness of in vitro diagnostic tests, including those for pathogen identification using in vitro nucleic acid testing, healthcare-associated illnesses (HAIs) such as pneumonia, urinary tract infections, and others, is assessed using IVD quality controls. These products primarily concentrate on defect detection, quality control, and validation panels like the Blood Culture (BCID) Control Panel, Human Papillomavirus (HPV) Control Panel, and others to support in the implementation and monitoring of the performance of clinical and research laboratories, blood diagnostic centers, and IVD manufacturers.
To Remain 'Ahead' Of Your Competitors, Request for A Sample – https://www.globalinsightservices.com/request-sample/GIS10301
Major Players in the Global In Vitro Diagnostic Quality Control Market
The key players studied in the global in vitro diagnostic quality control market are Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), Abbott Laboratories (US), Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Fortress Diagnostics (UK), SERO AS (US), Sysmex Corporation (Japan), Ortho-Clinical Diagnostics (US), and Helena Laboratories Corporation (US) among others.
Global In Vitro Diagnostics Quality Control Market Segmentation
By Product & Service
Quality Control Products
Data Management Solutions
Quality Assurance Services
By Technology
Immunochemistry
Clinical Chemistry
Molecular Diagnostics
Microbiology
Hematology
Coagulation/Hemostasis
Market Trends and Drivers
As the burden of various diseases increases globally, so has the number of laboratory tests. The number of laboratories in both the public and private sectors has increased in response to this need. With the start of the COVID-19 pandemic in December 2019, the demand for diagnostic tests has skyrocketed. Many government organizations have established new laboratories in response to this epidemic and to increase laboratory testing capacity. The majority of nations need clinical laboratories to get regulatory body accreditation before performing diagnostic tests. Additionally, accreditation to ISO 15189:2012 and other comparable standards is turning into a requirement in many nations. Authorities assess a laboratory’s competency and quality system during the accreditation process using predetermined standards. While some European nations, including Belgium, France, Hungary, Ireland, and Lithuania, require accreditation for a variety of laboratory tests, others, like Finland, the Netherlands, Sweden, Switzerland, and the UK, have practically finished the process.
With Global Insight Services, you receive:
· 10-year forecast to help you make strategic decisions
· In-depth segmentation which can be customized as per your requirements
· Free consultation with lead analyst of the report
· Excel data pack included with all report purchases
· Robust and transparent research methodology
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm
headquartered in Delaware, US. We are committed to providing our clients
with highest quality data, analysis, and tools to meet all their market research
needs. With GIS, you can be assured of the quality of the deliverables, robust
and transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700
0 notes
Text
In Vitro Diagnostic (IVD) Reagents Market Worth $77.6 Billion by 2027
In Vitro Diagnostic (IVD) Reagents Market Worth $77.6 Billion by 2027
According to this latest publication from Meticulous Research®, the IVD reagents market is expected to grow at a CAGR of 7% from 2020 to reach $77.6 billion by 2027. The high growth of the IVD reagents market is mainly attributed to the factors such as increasing global prevalence of acute and chronic infectious diseases coupled with rising geriatric population, increasing adoption of flow cytometry techniques in research and academia, increase in funding for research activities, and rising proteomics and genomics research studies. Moreover, the growing demand for protein therapeutics and personalized medicines and emerging economies offer significant growth opportunities for the players operating in this market. However, the unfavorable restrictions on approval procedure is expected to hamper the growth of the IVD reagents market to some extent.
The global IVD reagents market study presents historical market data in terms of values (2018 and 2019), estimated current data (2020), and forecasts for 2027- by type (oligonucleotide, antibodies, nucleic acid probe), technology (immunoassay, hematology, microbiology), use (research, analyte specific reagent), end user (IVD manufacturer, clinical laboratory), and geography. The study also evaluates industry competitors and analyzes the market at a country level.
Based on type, the antibodies segment is estimated to hold the largest share of the overall IVD reagents market in 2020. However, the oligonucleotides segment is expected to grow at the fastest CAGR during the forecast period. The fast growth of this segment is mainly attributed to the factors such as advancements in the field of genomics research, growing adoption of custom oligonucleotides, and rising strategic developments such as agreements and collaborations to expand oligonucleotides market.
Based on use, the research use segment is estimated to hold the largest share of the overall IVD reagents market in 2020. However, the clinical use segment is expected to grow with the fastest CAGR during the forecast period, mainly due to the factors such as rising adoption of advanced diagnostic modalities, growing importance of early disease diagnosis, number of diagnostic product launches, and demand for innovative reagents and assays for clinical usage.
Based on end user, the IVD manufacturers segment is estimated to command the largest share of the overall IVD reagents market in 2020. The factors such as rising number of research activities for the development of innovative IVDs, growing public and private funds, and rising demand for advanced disease diagnostics are expected to drive the growth of the IVD reagents market for IVD manufacturing during the forecast period. Moreover, the recent outbreak of COVID-19 is also expected to support the growth of the IVD reagents market for this segment. However, the clinical laboratories segment is expected to register the highest growth during the forecast period.
Geographic Review:
This research report analyzes major geographies and provides comprehensive analysis for North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is estimated to dominate the global IVD reagents market in 2020, followed by Europe and Asia Pacific. The factors such as growing healthcare sector, increasing need to treat various infectious diseases in early stage, increasing healthcare expenditure, and growing investments in personalized medicine and development of novel advanced technologies for diagnosis are supporting the largest share of North America in the global IVD reagents market.
𝑺𝒑𝒆𝒂𝒌 𝒕𝒐 𝑨𝒏𝒂𝒍𝒚𝒔𝒕:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5110?utm_source=prodyuct&utm_medium=Social&utm_campaign=Product&utm_content=15-12-2022
Key Players
The report includes competitive landscape based on the extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by the leading market players in the industry over the past 4 years (2017-2020). The key players profiled in the global IVD reagents market are Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), LGC Biosearch Technologies (U.K.), BioLegend, Inc. (U.S.), InBios International, Inc. (U.S.), LakePharma, Inc. (U.S.), Bioline (U.K.), Abcam plc (U.K.), The Binding Site Group Ltd.(U.K.), SDIX, LLC (U.S.), DIACLONE SAS (France), Bio-Techne Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Hologic Inc. (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), and Sino Biological Inc. (China).
Scope of the Report:
IVD Reagents Market, by Technology
Immunoassay/Immunochemistry
Enzyme-Linked Immunosorbent Assays (Elisa)
Western Blotting
Immunofluorescence
Immunohistochemistry
Functional Assays
Immunoprecipitation
Other Technologies
Biochemistry/Clinical Chemistry
Molecular Diagnostics
Microbiology
Hematology
Coagulation/Hemostatis
Urinalysis
Other Technologies
(Other Technologies comprises of hybridization and loop-mediated isothermal amplification among others)
IVD Reagents Market, by Type
Antibodies
Antibodies Market, By Type
Monoclonal
Polyclonal
Antibodies Market, By Target
CD
TCR
EGFR
Other Targets
Oligonucleotides
Nucleic Acid Probes
Purified Proteins or Peptides
Other Reagents
(Other reagents include Blocking Agents, Detergents, Surfactants, Wetting Agents, Buffers, Stabilizers, Purified Water, Dyes, Standards & Controls, Enzymes, Cell Culture Reagents, and Anti-coagulants)
IVD Reagents Market, by Use
Research Use Only
Analyte Specific Reagents
Clinical Use
IVD Reagents Market, by End User
IVD Manufacturers
Reference Laboratories
Academic and Research Institutes
Hospital Laboratories
IVD Reagents Market, by Geography
North America
U.S.
Canada
Europe
Germany
Italy
France
U.K.
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
Japan
China
India
Rest of Asia Pacific (RoAPAC)
Latin America
Middle East & Africa
𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑺𝒂𝒎𝒑𝒍𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 @https://www.meticulousresearch.com/download-sample-report/cp_id=5110?utm_source=prodyuct&utm_medium=Social&utm_campaign=Product&utm_content=15-12-2022
1 note
·
View note
Link
The remarkable growth rate of 6% is attributed to growing mergers & collaboration in this space coupled with growing government support in several...
0 notes
Text
The Future of Medical Device Outsourcing: Trends and Innovations
The global medical device outsourced manufacturing market size was USD 33.38 Billion in 2022 and is expected to register a revenue CAGR of 13.6% during the forecast period, according to the latest analysis by Emergen Research. Rising prevalence of chronic diseases such as diabetes and cardiovascular disease, rapid technological advancements in the product development of medical devices, and increased funding and investments toward early-stage medical technology-based startup companies are some of the key factors driving revenue growth of the medical device outsourced manufacturing market.
Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1760
Competitive Terrain:
The global Medical Device Outsourced Manufacturing industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
The leading market contenders listed in the report are:
Eakin Surgical., IQVIA., SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA., Eurofins Scientific, Bio-Rad Laboratories, Inc., Intertek Group plc, Charles River Laboratories, WuXi AppTec, Nipro Corporation, and Johari Digital
Key market aspects studied in the report:
Market Scope: The report explains the scope of various commercial possibilities in the global Medical Device Outsourced Manufacturing market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.
Competitive Outlook: The leading companies operating in the Medical Device Outsourced Manufacturing market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Medical Device Outsourced Manufacturing market.
Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1760
Market Segmentations of the Medical Device Outsourced Manufacturing Market
This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Medical Device Outsourced Manufacturing market on the basis of product, application, and region:
Segments Covered in this report are:
Device Type Outlook (Revenue, USD Billion; 2019-2032)
IVD Devices
Drug Delivery Devices
Diabetes Care Devices
Cardiovascular Devices
Diagnostic Imaging Devices
Surgical Devices
Others
Service Type Outlook (Revenue, USD Billion; 2019-2032)
Prototyping Development services
Pilot Production services
Device manufacturing services
Injection molding
CNC Machining and Laser Cutting & 3D Printing
Cleaning and Finishing
Others
Quality Management Services
Packaging Validation services
Inspection and Testing Services
Sterilization services
Others
Class of Medical Device Outlook (Revenue, USD Billion; 2019-2032)
Class I
Class II
Class III
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/medical-device-outsourced-manufacturing-market
Major Geographies Analyzed in the Report:
North America (U.S., Canada)
Europe (U.K., Italy, Germany, France, Rest of EU)
Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
ToC of the report:
Chapter 1: Market overview and scope
Chapter 2: Market outlook
Chapter 3: Impact analysis of COVID-19 pandemic
Chapter 4: Competitive Landscape
Chapter 5: Drivers, Constraints, Opportunities, Limitations
Chapter 6: Key manufacturers of the industry
Chapter 7: Regional analysis
Chapter 8: Market segmentation based on type applications
Chapter 9: Current and Future Trends
Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1760
0 notes
Text
Anatomic Pathology Market Opportunities, Threats, Drivers, Restraints, Trends, Applications, And Growth Forecast To 2030
The global anatomic pathology market forecast is set to reach US$ 61.1 Mn in revenues by 2030, according to a new market study by ESOMAR-certified market research firm, Future Market Insights (FMI).Anatomic Pathology Market Size (2022)US$ 32.5 MnAnatomic Pathology Market Revenue Forecast (2030)US$ 61.1 MnAnatomic Pathology Market Growth Rate (2022-2030)8.2% CAGRNorth America Market Share37.1%
The anatomic pathology market is subject to integrating medical informatics standards to meet specific healthcare requirements by curtailing costs and improvising on efficiency.
Pathology laboratories are on the verge of refurbishment as new-fangled disease diagnostic models are making a beeline therein.
As of now, lymphoma, breast cancer, colorectal cancer, prostate cancer, cervical cancer, and lung cancer are a part of anatomic pathology.
Key Takeaways
The instruments are subject to technological advancements, which would minimize errors. This factor is expected to drive the anatomic pathology market between 2022 and 2030
Consumables are expected to hold the largest market share due to low cost, high availability, and good purchase rate of probes and reagents
Academic research is bound to pick up pace in the forecast period owing to growing implementation of anatomic pathology in biomarker profiling and tumor examination
Preference to personalized therapies is prompting putative biomarkers being discovered. This factor is expected to be one of the key growth drivers
Key Participant Insights
The key market players are focusing on technological upgradations and expansion strategies to keep themselves fiercely competitive.
For instance –
In Jul 2020, Bio SB tabled its Fast Mohs PolyDetector Plus Detection System, which comes across as a super sensitive nonbiotin monovalent Fab micropolymer immunohistochemistry system to detect IVD antibodies for squamous cell carcinoma, basal cell carcinoma, and melanoma.
In Jan 2019, Quest Diagnostics announced completion of acquisition of the US laboratory services business that belonged to Oxford Immunotec (the T-Spot and Accutix tick-borne disease testing services, since then, are part of Quest’s infectious disease testing services.
In 2018, Leica Microsystems entered into a collaboration with Thermo Fisher to develop an integrated cryotomography workflow with regards to research.
For More information : https://www.futuremarketinsights.com/reports/anatomic-pathology-market
The other players in the veterinary imaging market include
Laboratory Corporation of America Holdings
Sakura Finetek USA, Inc.
F.Hoffmann-La Roche AG
Cardinal Health, Inc.
BioGenex
NeoGenomics
Agilent Technologies
The US continues to be one of the leading markets for anatomic pathology market globally. Strong presence of some of the leading players, combined with relatively easier funding for R&D will drive the US anatomic pathology market during the assessment period.
The Europe anatomic pathology market is also likely to grow at a brisk pace during the assessment period. The growth will remain concentrated in Western Europe, as has been the case traditionally.
Asia Pacific represents a high growth market for anatomic pathology stakeholders. Many countries in the region are renewing their focus on healthcare, as the current Covid-19 crisis has reinforced the necessity of a robust healthcare system.
Want more insights?
Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global anatomic pathology market is segmented in detail to cover every aspect and present a complete market intelligence approach to the reader.
The study provides compelling insights on anatomic pathology market on the basis of product & services type (Instruments (Microtomes & Cryostat, Tissue processors, Automatic Stainers, and Other products), consumables (Reagents & Antibodies, Probes & Kits, and Others), application (Disease Diagnosis, Drug Discovery and Development, and Others), and services (histopathology, cytopathology)) across seven geographies.
Inquire Before Buying This Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-12370
Key Segments of Anatomic Pathology Industry Survey
Anatomic Pathology Market by Product & Service:
Anatomic Pathology Instruments
Anatomic Pathology Consumables
Anatomic Pathology Services
Anatomic Pathology Market by Application:
Disease Diagnosis
Drug Discovery and Development
Others
Anatomic Pathology Market by End User:
Hospitals
Research Laboratories
Diagnostic Laboratories
Others
0 notes
Text
Vitro Diagnostics (IVD) Market Size 2020 Demand, Global Trend, News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2026
Vitro Diagnostics (IVD) Market Size 2020 Demand, Global Trend, News, Business Growth, Top Key Players Update, Business Statistics and Research Methodology by Forecast to 2026
Vitro Diagnostics (IVD) Industry Market Report Coverage: Key Growth Factors & Challenges, Segmentation & Regional Outlook, Top Industry Trends & Opportunities, Competition Analysis, COVID-19 Impact Analysis & Projected Recovery, and Market Sizing & Forecast A recent market research report added to repository of Credible Markets is an in-depth analysis of Global Vitro Diagnostics (IVD) Industry…
View On WordPress
#Global Vitro Diagnostics (IVD) Market#North America Vitro Diagnostics (IVD) Market#Vitro Diagnostics (IVD) Applications#Vitro Diagnostics (IVD) Industry#Vitro Diagnostics (IVD) Key Players#Vitro Diagnostics (IVD) Market#Vitro Diagnostics (IVD) Market 2019#Vitro Diagnostics (IVD) Market 2020
0 notes
Text
In Vitro Diagnostic (IVD) Reagents Market Worth $77.6 Billion by 2027
According to this latest publication from Meticulous Research®, the IVD reagents market is expected to grow at a CAGR of 7% from 2020 to reach $77.6 billion by 2027. The high growth of the IVD reagents market is mainly attributed to the factors such as increasing global prevalence of acute and chronic infectious diseases coupled with rising geriatric population, increasing adoption of flow cytometry techniques in research and academia, increase in funding for research activities, and rising proteomics and genomics research studies. Moreover, the growing demand for protein therapeutics and personalized medicines and emerging economies offer significant growth opportunities for the players operating in this market. However, the unfavorable restrictions on approval procedure is expected to hamper the growth of the IVD reagents market to some extent.
The global IVD reagents market study presents historical market data in terms of values (2018 and 2019), estimated current data (2020), and forecasts for 2027- by type (oligonucleotide, antibodies, nucleic acid probe), technology (immunoassay, hematology, microbiology), use (research, analyte specific reagent), end user (IVD manufacturer, clinical laboratory), and geography. The study also evaluates industry competitors and analyzes the market at a country level.
Based on type, the antibodies segment is estimated to hold the largest share of the overall IVD reagents market in 2020. However, the oligonucleotides segment is expected to grow at the fastest CAGR during the forecast period. The fast growth of this segment is mainly attributed to the factors such as advancements in the field of genomics research, growing adoption of custom oligonucleotides, and rising strategic developments such as agreements and collaborations to expand oligonucleotides market.
Based on use, the research use segment is estimated to hold the largest share of the overall IVD reagents market in 2020. However, the clinical use segment is expected to grow with the fastest CAGR during the forecast period, mainly due to the factors such as rising adoption of advanced diagnostic modalities, growing importance of early disease diagnosis, number of diagnostic product launches, and demand for innovative reagents and assays for clinical usage.
Based on end user, the IVD manufacturers segment is estimated to command the largest share of the overall IVD reagents market in 2020. The factors such as rising number of research activities for the development of innovative IVDs, growing public and private funds, and rising demand for advanced disease diagnostics are expected to drive the growth of the IVD reagents market for IVD manufacturing during the forecast period. Moreover, the recent outbreak of COVID-19 is also expected to support the growth of the IVD reagents market for this segment. However, the clinical laboratories segment is expected to register the highest growth during the forecast period.
Geographic Review:
This research report analyzes major geographies and provides comprehensive analysis for North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is estimated to dominate the global IVD reagents market in 2020, followed by Europe and Asia Pacific. The factors such as growing healthcare sector, increasing need to treat various infectious diseases in early stage, increasing healthcare expenditure, and growing investments in personalized medicine and development of novel advanced technologies for diagnosis are supporting the largest share of North America in the global IVD reagents market.
𝑺𝒑𝒆𝒂𝒌 𝒕𝒐 𝑨𝒏𝒂𝒍𝒚𝒔𝒕:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5110?utm_source=prodyuct&utm_medium=Social&utm_campaign=Product&utm_content=15-12-2022
Key Players
The report includes competitive landscape based on the extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by the leading market players in the industry over the past 4 years (2017-2020). The key players profiled in the global IVD reagents market are Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), LGC Biosearch Technologies (U.K.), BioLegend, Inc. (U.S.), InBios International, Inc. (U.S.), LakePharma, Inc. (U.S.), Bioline (U.K.), Abcam plc (U.K.), The Binding Site Group Ltd.(U.K.), SDIX, LLC (U.S.), DIACLONE SAS (France), Bio-Techne Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Hologic Inc. (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), and Sino Biological Inc. (China).
Scope of the Report:
IVD Reagents Market, by Technology
Immunoassay/Immunochemistry
Enzyme-Linked Immunosorbent Assays (Elisa)
Western Blotting
Immunofluorescence
Immunohistochemistry
Functional Assays
Immunoprecipitation
Other Technologies
Biochemistry/Clinical Chemistry
Molecular Diagnostics
Microbiology
Hematology
Coagulation/Hemostatis
Urinalysis
Other Technologies
(Other Technologies comprises of hybridization and loop-mediated isothermal amplification among others)
IVD Reagents Market, by Type
Antibodies
Antibodies Market, By Type
Monoclonal
Polyclonal
Antibodies Market, By Target
CD
TCR
EGFR
Other Targets
Oligonucleotides
Nucleic Acid Probes
Purified Proteins or Peptides
Other Reagents
(Other reagents include Blocking Agents, Detergents, Surfactants, Wetting Agents, Buffers, Stabilizers, Purified Water, Dyes, Standards & Controls, Enzymes, Cell Culture Reagents, and Anti-coagulants)
IVD Reagents Market, by Use
Research Use Only
Analyte Specific Reagents
Clinical Use
IVD Reagents Market, by End User
IVD Manufacturers
Reference Laboratories
Academic and Research Institutes
Hospital Laboratories
IVD Reagents Market, by Geography
North America
U.S.
Canada
Europe
Germany
Italy
France
U.K.
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
Japan
China
India
Rest of Asia Pacific (RoAPAC)
Latin America
Middle East & Africa
𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑺𝒂𝒎𝒑𝒍𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 @https://www.meticulousresearch.com/download-sample-report/cp_id=5110?utm_source=prodyuct&utm_medium=Social&utm_campaign=Product&utm_content=15-12-2022
0 notes
Link
The remarkable growth rate of 6% is attributed to growing mergers & collaboration in this space coupled with growing government support in several...
0 notes